secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caribou Biosciences, Inc. (CRBU)
CIK:        0001619856
Form:       8-K
Filed at:   2024-04-04T23:59:59+00:00
Accession:  0001619856-24-000018
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Caribou Biosciences receives FDA IND clearance for CB-010 in lupus; GALLOP Ph1 trial expected by YE 2024
--------------------------------------------------------------------------------

- FDA cleared IND for CB-010 (allogeneic anti-CD19 CAR-T) to treat lupus nephritis and extrarenal lupus.
- Phase 1 GALLOP trial expected to initiate by year-end 2024; evaluates safety of single infusion with partial HLA matching.
- CB-010 clinical development expanded from oncology to autoimmune diseases; driven by encouraging initial ANTLER trial data in r/r B-NHL.
- Caribou reports $372.4M cash as of Dec 31, 2023, expected to fund operations into Q1 2026.
- Initial dose expansion data from ANTLER Phase 1 trial for 2L LBCL to be presented at a medical congress in Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1619856/000161985624000018/0001619856-24-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1619856/000161985624000018/crbu-20240404.htm
  HTML page:      https://secwatch.observer/filing/0001619856-24-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer